ArticleDiscover oncology2025
The role of cellular heterogeneity in thyroid cancer: a multi-modal analysis approach with Mendelian randomization.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision medicine in thyroid nodules: current strategies, challenges, and future directions.Hormones (Athens, Greece) · 2026Review
- Unravelling SLC7 family members in thyroid cancer and translational barriers.American journal of cancer research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThyroid cancer pathogenesis involves complex interactions between genetic predisposition and alterations in the tumor microenvironment. The causal relationships between inflammatory gene variants and thyroid cancer risk remain poorly understood, as does the cellular heterogeneity within the tumor ecosystem. This study aimed to investigate the causal associations between inflammatory protein genes and thyroid cancer risk, and to characterize the cellular composition and differentiation trajectories within the thyroid cancer microenvironment.
methodsWe employed a two-pronged approach combining Mendelian randomization (MR) analysis and single-cell RNA sequencing (scRNA-seq). MR analyses were conducted using genetic variants associated with the expression of inflammatory proteins (4EBP1_EIF4EBP1, ADA_ADA, ARTN_ARTN, AXIN1_AXIN1, and Beta-NGF_NGF) as instrumental variables to assess their causal effects on thyroid cancer risk. Multiple MR methods (MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode) were used to enhance robustness. For the cellular characterization, scRNA-seq was performed on thyroid cancer samples, followed by dimensionality reduction, clustering analysis, cell type annotation, and pseudotime trajectory inference.
resultsMR analyses revealed a significant positive causal association between AXIN1_AXIN1 expression and thyroid cancer risk (weighted median: OR = 1.396, p < 0.05; inverse variance weighted: OR = 1.291, p < 0.05), while ADA_ADA showed protective effects (simple mode: OR = 0.731, p < 0.05). The scRNA-seq analysis identified six major cell populations within the thyroid cancer microenvironment: epithelial cells, T cells, natural killer cells, fibroblasts, stromal cells, and macrophages. Pseudotime analysis revealed distinct differentiation trajectories with natural killer cells and macrophages appearing in early pseudotime, while epithelial cells and fibroblasts demonstrated multiple developmental states. Gene expression profiling identified four distinct cellular states with unique molecular signatures, including immune/inflammatory, stromal, and vascular components.
conclusionOur findings suggest that inflammatory protein genes, particularly AXIN1, have causal effects on thyroid cancer risk, providing potential targets for risk prediction and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.